Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

for REOLYSIN to commercial scale. Financial and Intellectual Property ----------------------------------- - In December, Oncolytics closed a public offering that added a net $3.4 million to Oncolytics' financial reserves, bringing the total to $13.3 million in cash and equivalents at December 31, 2008; and, - Secured five U.S. and three Canadian patents in 2008. Currently more than 200 patents have been issued worldwide, including 31 US and 9 Canadian. "We are greatly encouraged by the clinical results we are seeing in our clinical trials, and by the continued enthusiasm displayed by our collaborators," said Dr. Thompson. "We look forward to taking REOLYSIN into to the final stages of development in 2009." Oncolytics Biotech Inc. CONSOLIDATED BALANCE SHEETS As at December 31 2008 2007 $ $ ------------------------------------------------------------------------- ASSETS Current Cash and cash equivalents 7,429,895 6,715,096 Short-term investments 5,846,634 18,498,733 Accounts receivable 86,322 80,085 Prepaid expenses 179,668 260,300 ------------------------------------------------------------------------- 13,542,519 25,554,214 Property and equipment 263,926 201,103 Intellectual property 180,750 542,250 ------------------------------------------------------------------------- 13,987,195 26,297,567 ---------------------
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Robin Williams’ passing is ... take on an individual. Symptoms range from slowness ... problems swallowing and severe depression. Parkinson’s disease progressively ... of dopamine producing neurons of the brain. As ... that slowly and progressively gets worse, they look for ...
(Date:8/19/2014)... Md. , Aug. 19, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today that its novel ... at the 54 th Interscience Conference on ... Washington D.C. ...
(Date:8/18/2014)... Diagnostics Inc. (TSX-V: SQD), a life sciences company that ... microarray diagnostics, today announced it will hold an investor ... ET.  During the call, Andrew ... SQI,s recent commercialization progress and then introduce Dr. ... to the Board of Directors of SQI and also ...
(Date:8/18/2014)... YORK , August 18, 2014 ... published by Transparency Market Research "Life Science Reagents ... Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and ... and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- ... Forecast, 2013 - 2019", the global life science ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... research center. The facility would be built between University ... Madison, Wis. Wisconsin should hold on to its ... million in public and private funding for a new research ... Doyle said on Wednesday. , ,He also called for ...
... have been transformed into specific cells of the body. Courtesy ... Madison, Wis. The answer to reversing the ... may lie in stem-cell treatment, according to the ongoing research ... Life Sciences and Venture Conference held Wednesday at Monona ...
... Bureau of Labor and Statistics projections: by 2006 two employees ... 2008, there will be a national shortage of ten million ... job loss, and when off-shoring is becoming de rigueur, these ... common arguments I hear refuting BLS statistics, along with my ...
Cached Biology Technology:Wisconsin governor calls for $750 million investment in life sciences 2Wisconsin governor calls for $750 million investment in life sciences 3Wisconsin governor calls for $750 million investment in life sciences 4Wisconsin governor calls for $750 million investment in life sciences 5UW-Madison puts heart and mind into stem cells 2UW-Madison puts heart and mind into stem cells 3Talent shortage? Cmon. 2
(Date:8/19/2014)... week,s Eos: Long-Term Ecological Research and Network-Level Science, , ... a wide range of ecosystems was responding to global ... particularly powerful if it coupled multiple decades of information ... experiments and models from dozens of different ecosystem types. ... the Long-Term Ecological Research (LTER) Network, which will soon ...
(Date:8/19/2014)... measurements from fish purchased at retail seafood counters ... which mislabeling can expose consumers to unexpectedly high ... stock "substitutions"which falsely present a fish of the ... the most dangerous mislabeling offense, according to new ... , "Accurate labeling of seafood is essential to ...
(Date:8/19/2014)... Some infants born with neonatal abstinence syndrome ... more difficult time going through withdrawal than others, ... While genetic and epigenetic (when genes are turned ... as potential factors, researchers at Boston University School ... conducted a first of its kind study to ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... controlled trial of fish oil given intravenously to patients ... exchange, reduces inflammatory chemicals and results in a shorter ... open access journal Critical Care investigated the ... solution for patients with sepsis, finding a significant series ...
... 1. Prescribed Opioids Associated with Significant Risk for ... oxycodone, have increased significantly over the past decade. As ... common, the deaths associated with opioids increase. Opioid overdose ... Researchers sought to determine the rate of opioid overdose ...
... MIT and Harvard Medical School have built targeted nanoparticles ... medicine, an advance that potentially provides an alternative to ... The particles, dubbed "nanoburrs" because they are coated with ... target proteins, can be designed to release their drug ...
Cached Biology News:Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 2Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 3New nanoparticles target cardiovascular disease 2
... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... is specifically designed to target and display ... cerevisiae. Displayed proteins can be analyzed for ... putative ligands. pYD1 uses the a-agglutinin yeast ... Aga1 and Aga2, to display recombinant protein ...
... Drosophila S2 cells are used for ... Expression System (DES). The S2 cell line ... stage (20-24 hours old) Drosophila melanogaster ... rapidly at room temperature without CO2 and is ...
Biology Products: